Randomized trial · people
Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In early testing in type 2 diabetes, the higher retatrutide doses lowered blood sugar and weight versus placebo over 12 weeks, with gut side effects the most common complaint.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 72
- Published
- 2022
- Journal
- Lancet
What they tested
The team tested whether weekly shots of retatrutide (LY3437943) were safe and tolerable in people with type 2 diabetes, and how the drug behaved in the body and affected blood sugar and weight.
How the study was done
A randomized, double-blind, placebo-controlled phase 1b trial in 72 adults with type 2 diabetes at four US centers, who got weekly injections for 12 weeks. People received one of five rising retatrutide doses, placebo (a dummy shot), or dulaglutide 1.5 mg, with the two highest doses reached by stepping up over time.

Model. Individual results vary.
What they found
Side effects that started during treatment affected 33 (63%) people on retatrutide, 60% of those on dulaglutide and 54% of those on placebo, and stomach and gut problems were the most common. The drug's half-life, the time for half of it to leave the body, was about 6 days. Compared with placebo at week 12, the 3 mg, 3/6 mg and 3/6/9/12 mg groups lowered average daily blood sugar by 2.8, 3.1 and 2.9 mmol/L, and lowered sHbA1c, a measure of average blood sugar, by 1.4%, 1.6% and 1.2%. Weight loss seemed to rise with dose, reaching 8.96 kg more than placebo in the 3/6/9/12 mg group.
What it doesn’t show
This was a small, 12-week early-phase trial built mainly to check safety, with small groups at each retatrutide dose and 29 people leaving the study early. It was funded by Eli Lilly and Company.
The paper
Urva et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022.
The compound
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.